Dr Reddy's launches diabetic drug
Pharma major Dr Reddy's forays in triple drug combination oral hypoglycemic agents market.
By PTI |
MUMBAI: Pharma major Dr Reddy's Laboratories on Tuesday launched its anti-diabetes drug 'Glimy MP1 and Glimy MP2', marking its entry in the triple drug combination oral hypoglycemic agents market.
Glimy MP is an extension of the existing products of the company, used in the management of Type 2 diabetes.
It is a one step approach to intensive glycemic control, Dr Reddy's said in a filing to the Bombay Stock Exchange.
The triple drug combination offers the range of options available for the doctor to address their needs in different situations in the management of Type 2 diabetes.
Glimy MP is an extension of the existing products of the company, used in the management of Type 2 diabetes.
It is a one step approach to intensive glycemic control, Dr Reddy's said in a filing to the Bombay Stock Exchange.
The triple drug combination offers the range of options available for the doctor to address their needs in different situations in the management of Type 2 diabetes.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
